Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 5, 2015, Pages 506-513

  Abasolo, Lydia ^a   Leon, Leticia ^a,b   Rodriguez Rodriguez, Luis ^a   Tobias, Aurelio ^c   Rosales, Zulema ^a   Maria Leal, Jose ^a   Castaño, Victor ^a   Vadillo, Cristina ^a   Macarron, Pilar ^a   Fontsere, Oscar ^a   Jover, Juan Angel ^a,d  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^c CSIC   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Adverse drug reactions; Biological agents; Disease modifying antirheumatic drugs; Incidence rates; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIMALARIAL AGENT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; AGING; ALLERGY; ALOPECIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISABILITY; DISEASE DURATION; DRUG SAFETY; DRUG WITHDRAWAL; EDUCATION; ERYTHROCYTE SEDIMENTATION RATE; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MUSCLE DISEASE; NEOPLASM; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PANCREAS DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SKIN DISEASE; SPAIN; TREATMENT DURATION; UROGENITAL TRACT DISEASE; AGED; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; FACTUAL DATABASE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84926420218     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.11.003     Document Type: Article

References (51)

1. Carmona L., Villaverde V., Hernandez-Garcia C., Ballina J., Gabriel R., Laffon A., et al. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford) 2002, 41:88-95.
2. Spector T.D. Rheumatoid arthritis. Rheum Dis Clin North Am 1990, 16:513-537.
3. Katz P.P., Morris A., Yelin E.H. Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis. Ann Rheum Dis 2006, 65:763-769.
4. Pincus T., Callahan L.F., Sale W.G., Brooks A.L., Payne L.E., Vaughn W.K. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984, 27:864-872.
5. Grigor C., Capell H., Stirling A., McMahon A.D., Lock P., Vallance R., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004, 364:263-269.
6. Saunders S.A., Capell H.A., Stirling A., Vallance R., Kincaid W., McMahon A.D., et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008, 58:1310-1317.
7. Bykerk V.P., Akhavan P., Hazlewood G.S., Schieir O., Dooley A., Haraoui B., et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012, 39:1559-1582.
8. Black N. Why we need observational studies to evaluate the effectiveness of health care. Br Med J 1996, 312:1215-1218.
9. McKee M., Britton A., Black N., McPherson K., Sanderson C., Bain C. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. Br Med J 1999, 319:312-315.
10. Singh J.A., Cameron D.R. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults-an update. J Manag Care Pharm 2012, 18(4 Suppl. C):S1-18.
11. Ma M.H., Kingsley G.H., Scott D.L. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2010, 49:91-98.
12. Singer O., Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?. Curr Opin Rheumatol 2011, 23:288-292.
13. Aaltonen K.J., Virkki L.M., Malmivaara A., Konttinen Y.T., Nordstrom D.C., Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012, 7:e30275.
14. Donahue K.E., Gartlehner G., Jonas D.E., Lux L.J., Thieda P., Jonas B.L., et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008, 148:124-134.
15. WHO. ed. Draft guidelines for adverse event reporting and learning systems. Printed by the WHO Document Production Services, Geneva, Switzerland; 2005.
16. Rosser R., Kind P. A scale of valuations of states of illness: is there a social consensus?. Int J Epidemiol 1978, 7:347-358.
17. Rosales Z., Rodríguez-Cambrón A.B., Abásolo L., León L., Fontsere O., Vadillo C., et al. Detection of Adverse Events in Routine Rheumatology Practice by a New Computer Aplication. Póster. Lugar: Congreso Americano de Reumatología (ACR). Chicago. Año 2011.
18. Carmona L., Gonzalez-Alvaro I., Balsa A., Belmonte M., Tena X., Sanmarti R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 2003, 62:897-900.
19. Bombardier C., Hazlewood G.S., Akhavan P., Schieir O., Dooley A., Haraoui B., et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol 2012, 39:1583-1602.
20. Smolen J., Landewé R., Breedveld F., Dougados M., Emery P., Gaujoux-Viala Cecile, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
21. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic ugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
22. Blanco F.J., Ballina J., Carbonell J., Martin-Mola E., Tornero J., Ramirez E., et al. Descriptive study of the use of DMARD in patients with rheumatoid arthritis or persistent arthritis who start drug treatment in Spain (FIRST). Reumatol Clin 2011, 7:88-93.
23. Nikolaisen C., Kvien T.K., Mikkelsen K., Kaufmann C., Rodevand E., Nossent J.C. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway. Scand J Rheumatol 2009, 38:240-245.
24. Gibofsky A., Palmer W.R., Goldman J.A., Lautzenheiser R.L., Markenson J.A., Weaver A., et al. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. Curr Med Res Opin 2006, 22:169-183.
25. Aletaha D., Kapral T., Smolen J.S. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 2003, 62:482-486.
26. Lacaille D., Guh D.P., Abrahamowicz M., Anis A.H., Esdaile J.M. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008, 59:1074-1081.
27. Ventura-Ríos L., Bañuelos-Ramírez D., Hernández-Quiroz M.C., Robles-San Román M., Irazoque-Palazuelos F., Goycochea-Robles M.V. Terapia biológica: sobrevida y seguridad en padecimientos reumáticos. Resultados del Registro Nacional Biobadamex 1.0. Reumatol Clin 2012, 8:189-194.
28. Grove M.L., Hassell A.B., Hay E.M., Shadforth M.F. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM 2001, 94:309-319.
29. Maetzel A., Wong A., Strand V., Tugwell P., Wells G., Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000, 39:975-981.
30. La Montagna G., Tirri R., Vitello R., Malesci D., Buono R., Mennillo G., et al. Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice. Reumatismo 2006, 58:261-267.
31. Van Roon E.N., Jansen T.L., Mourad L., Houtman P.M., Bruyn G.A., Griep E.N., et al. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharmacol 2004, 57:790-797.
32. Bettembourg-Brault I., Gossec L., Pham T., Gottenberg J.E., Damiano J., Dougados M. Leflunomide in rheumatoid arthritis in daily practice: treatment discontinuation rates in comparison with other DMARDs. Clin Exp Rheumatol 2006, 24:168-171.
33. Alcorn N., Saunders S., Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009, 32:1123-1134.
34. Jover J.A., Leon L., Pato E., Loza E., Rosales Z., Matias M.A., et al. Long-term use of antimalarial drugs in rheumatic diseases. Clin Exp Rheumatol 2012, 30:380-387.
35. Kinder A.J., Hassell A.B., Brand J., Brownfield A., Grove M., Shadforth M.F. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford) 2005, 44:61-66.
36. Marchesoni A., Zaccara E., Gorla R., Bazzani C., Sarzi-Puttini P., Atzeni F., et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009, 1173:837-846.
37. Gaujoux-Viala C., Smolen J.S., Landewe R., Dougados M., Kvien T.K., Mola E.M., et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69:1004-1009.
38. Sfriso P., Salaffi F., Montecucco C.M., Bombardieri S., Todesco S. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice. Reumatismo 2009, 61:132-139.
39. Malysheva O.A., Wahle M., Wagner U., Pierer M., Arnold S., Hantzschel H., et al. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J Rheumatol 2008, 35:979-985.
40. Saag K.G., Koehnke R., Caldwell J.R., Brasington R., Burmeister L.F., Zimmerman B., et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994, 96:115-123.
41. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995, 9:619-632.
42. Pascual-Ramos V., Contreras-Yanez I., Villa A.R., Cabiedes J., Rull-Gabayet M. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther 2009, 11:R26.
43. Choy E.H., Smith C., Dore C.J., Scott D.L. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 2005, 44:1414-1421.
44. Dougados M., Combe B., Cantagrel A., Goupille P., Olive P., Schattenkirchner M., et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999, 58:220-225.
45. Rodriguez-Rodriguez L., Jover-Jover J.A., Fontsere O., Pena-Blanco R.C., Leon L., Fernandez-Gutierrez B., et al. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis. Scand J Rheumatol 2013, 42:433-436.
46. Osiri M., Shea B., Robinson V., Suarez-Almazor M., Strand V., Tugwell P., et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003, 1:CD002047.
47. Cannon G.W., Holden W.L., Juhaeri J., Dai W., Scarazzini L., Stang P. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol 2004, 31:1906-1911.
48. Katchamart W., Trudeau J., Phumethum V., Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009, 68:1105-1112.
49. Capell H.A., Madhok R., Porter D.R., Munro R.A., McInnes I.B., Hunter J.A., et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007, 66:235-241.
50. Burmester G.R., Mariette X., Montecucco C., Monteagudo-Saez I., Malaise M., Tzioufas A.G., et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007, 66:732-739.
51. Finckh A., Dehler S., Gabay C., doctors S. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2009, 68:33-39.